In North America and in many European countries, pre-operative 5-fluorouracil (5-FU) and radiation followed by total mesorectal excision (TME) and post-operative adjuvant 5-FU is one of the standard treatments for locally advanced rectal cancer (LARC) stage II and III. This approach has resulted in a five-year cumulative local relapse rate of less than 10 % and an incidence of distant metastases of about 35 %. Figure 1 ). Although the reasons for this
Pre-operative versus Post-operative Chemoradiotherapy
Two Phase III trials compared pre-operative with post-operative chemoradiotherapy in clinical stages T3 or T4 or N+ rectal cancer.
In the German CAO/ARO/AIO (Chirurgische Arbeitsgemeinschaft
Onkologie/Arbeitsgemeinschaft Radioonkologie/Arbeitsgemeinschaft Internistische Onkologie) 94 trial, 1 patients who received pre-operative therapy had a significantly lower incidence of local recurrence (6 % versus 13 %; p=0.006), a significantly lower incidence of acute (27 % versus 40 %; p=0.001) and chronic (14 % versus 24 %; p=0.012) toxicity, a higher incidence of sphincter preservation (39 % versus 20 %; p=0.005), and no difference in five-year survival (74 % versus 76 %) or five-year cumulative distant recurrence rates (36 % versus 38 %). Updated data after a median follow-up of 11 years showed a persisting significant improvement of local control following pre-operative versus post-operative chemoradiotherapy. However, there was no effect on OS. 4 The NSABP (National Surgical Adjuvant Breast and Bowel Project) R-03 trial 5 was the first to document a significant improvement in 267 patients were recruited instead of the 900 patients the investigators had originally planned to enroll, which limited the trial's statistical power to detect differences. In contrast, the CAO/ARO/AIO 94 trial 1 succeeded in randomly assigning more than 800 patients to treatment, with longterm follow-up data confirming the results, and it therefore remains the definitive trial of chemoradiotherapy in rectal cancer. 6 
Pre-operative Radiotherapy with or without Concurrent Chemotherapy
The second question is whether or not conventional pre-operative chemoradiotherapy is better than radiotherapy alone in LARC. Three recent Phase III trials have tackled this issue.
The French FFCD 9203 trial 3 (ClinicalTrials.gov identifier NCT00296608) randomized resectable stage T3/T4 patients with rectal adenocarcinoma to receive pre-operative radiotherapy (45 Gy) with or without concurrent bolus 5-FU/leucovorin. Surgery was planned three to 10 weeks after the end of radiotherapy. All patients were to receive the same adjuvant chemotherapy regimen of 5-FU/leucovorin. Pathological complete response (pCR) was more frequent with chemoradiotherapy (11.4 % versus 3.6 %; p<0.05). The five-year incidence of local recurrence was lower with chemoradiotherapy (8.1 % versus 16.5 %; p<0.05).
However, there was no difference between the two arms in five-year progression-free survival (PFS) or OS. were randomized to one of four treatment arms:
• pre-operative radiotherapy (45 Gy over five weeks) alone;
• pre-operative radiotherapy plus two five-day chemotherapy courses with bolus 5-FU and leucovorin in week 1 and 5 of radiotherapy;
• pre-operative radiotherapy plus four post-operative courses of chemotherapy (bolus 5-FU/leucovorin); or
• pre-operative and chemotherapy plus post-operative chemotherapy.
The five-year cumulative incidence rates for local recurrences were 8.7 %, 9.6 %, and 7.6 % in the groups who received chemotherapy pre-operatively, post-operatively, or both, respectively, and 17.1 % in the group that did not receive chemotherapy (p=0.002). No differences were observed between the four arms in distant disease relapse.
Overall, the five-year cumulative incidence of distant metastases was 34.4 %. The authors therefore concluded that, regardless of timing, chemotherapy provides a significant benefit with respect to local control. No beneficial effects were seen in PFS and OS in the chemoradiotherapy groups versus the radiotherapy group.
The third trial 7 included 207 patients with locally non-resectable T4 rectal cancer or local recurrence who received either pre-operative chemotherapy (5-FU/leucovorin) administered concurrently with radiotherapy (50 Gy) plus adjuvant chemotherapy for 16 weeks after surgery, or pre-operative radiotherapy alone (50 Gy). Local control (82 % versus 67 % at five years; p=0.03) and cancer-specific survival (72 % versus 55 %; p=0.02) rates were better in the chemoradiotherapy group. However, once again, there were no differences in OS. It should be noted that, in the three trials described above, acute grade 2 or higher toxicity (mainly gastrointestinal) was significantly more common, although staying within safe limits, in patients assigned to pre-operative chemoradiotherapy. No differences were noted in late toxicity.
Adjuvant or Induction Chemotherapy in Locally Advanced
Rectal Cancer O N C O L O G Y & H E M A T O L O G Y R E V I E W
Adjuvant Therapy After Chemoradiotherapy and Surgery
The benefit of adjuvant therapy after pre-operative chemoradiotherapy has not been well established in randomized trials. Third, the survival curves of patients who received post-operative adjuvant chemotherapy begin to diverge after two years for DFS and after four years for OS from those of patients who did not receive adjuvant chemotherapy, suggesting that further follow-up is required to determine whether these divergences will continue.
An updated analysis was subsequently performed to determine the long-term results of the EORTC 22921 trial. 14 The goal of this exploratory multivariate analysis was to investigate whether it would be possible to identify a subgroup of patients who would benefit most from adjuvant chemotherapy in the long term. Adjuvant chemotherapy did not improve DFS or OS in all patients with resectable T3/T4 rectal cancer. However, a subset analysis revealed that patients whose disease responded to neoadjuvant therapy-specially those whose tumors were downstaged from ypT3-4 to ypT0-2 with pre-operative therapy-did experience survival benefits from adjuvant chemotherapy.
More recently, a large retrospective analysis explored the same issue; 2,724 patients were included, 41 % of whom underwent adjuvant chemotherapy (mostly 5-FU-based). 15 The aim was to Overall, these results support the equivalence in both efficacy and safety of capecitabine and IV infusional 5-FU in the pre-operative chemoradiotherapy management of rectal cancer patients.
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Fluoropyrimidines versus Fluoropyrimidines with Oxaliplatin Concomitant with Radiotherapy
One approach to improve outcomes in rectal cancer is to deliver a second radiation-sensitizing drug with effective systemic activity. The other efficacy endpoints (i.e., R0 resection and good TME surgery).
In summary, up to now, the impact of neoadjuvant oxaliplatin in rectal cancer-if any-has been small. The CAO/ARO/AIO-04 trial was the only one to show a small but significant difference in pCR rates in patients who had oxaliplatin added to their treatment. Other secondary efficacy endpoints were similar in all the trials mentioned above (summarized in Table 1 ). As the follow-up has been short, no data regarding primary endpoints are currently available. Table 2 .
Induction Chemotherapy Followed by Concomitant Chemoradiotherapy and Surgery
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Data from Randomized Trials
On the basis of these encouraging results, our study group (Grupo Cáncer de Recto) designed a phase II randomized trial to compare this approach with conventional pre-operative chemoradiotherapy followed by surgery and post-operative adjuvant chemotherapy (see Figure 2 ).
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A total of 108 patients with LARC defined by MRI of the pelvis were randomly assigned to either pre-operative chemoradiotherapy with CAPOX and concurrent radiation followed by surgery and four cycles of post-operative adjuvant CAPOX, or induction CAPOX followed by chemoradiotherapy and surgery. MRI criteria for defining LARC were as follows: tumors extending 2 mm within or beyond the mesorectal fascia (i.e., an involved or threatened CRM); lower third (≤6 cm from the anal verge) cT3 tumors; resectable cT4 tumors; or any cT3N+ tumors. The primary endpoint was the pCR rate. On an ITT basis, the pCR rate was 13.5 % (95 % CI 5.6-25.8 %) with the standard strategy (adjuvant chemotherapy) and 14.3 % (95 % CI 6.4-26.2 %) with the induction strategy. There were no statistically significant differences in other endpoints, including downstaging, tumor regression, and R0 resection.
The most compelling results from this study concern the secondary endpoints. During the course of chemoradiotherapy, there were no differences between the study arms in the number of patients with grade 3-4 toxicity. However, during the course of chemotherapy, significantly more patients had grade 3-4 toxicity in the adjuvant arm than in the induction arm (54 % versus 19 %, respectively; p=0.0004).
Furthermore, 25 % of patients in the adjuvant arm did not begin treatment and only 57 % received all four cycles, whereas 100 % of patients in the induction arm began treatment and 94 % received all four cycles (see Table 3 ). These differences reached statistical significance. 
